Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) EPS (Weighted Average and Diluted) (2017 - 2025)

Historic EPS (Weighted Average and Diluted) for NovaBay Pharmaceuticals (NBY) over the last 11 years, with Q3 2025 value amounting to -$0.23.

  • NovaBay Pharmaceuticals' EPS (Weighted Average and Diluted) rose 9072.58% to -$0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.82, marking a year-over-year decrease of 405.9%. This contributed to the annual value of -$0.31 for FY2020, which is 3541.67% up from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' EPS (Weighted Average and Diluted) is -$0.23, which was up 9072.58% from -$2.48 recorded in Q3 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at -$0.23 during Q3 2025, and registered a low of -$29.95 during Q1 2024.